In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America

Página do item simplificado
dc.contributor.authorGales, Ana Cristina [UNIFESP]
dc.contributor.authorJones, Ronald N.
dc.contributor.authorAndrade, Soraya Sgambatti [UNIFESP]
dc.contributor.authorPereira, Andrea dos Santos [UNIFESP]
dc.contributor.authorSader, Helio Silva [UNIFESP]
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionDepartment of Medicine
dc.contributor.institutionThe JMI Laboratories
dc.date.accessioned2015-06-14T13:31:45Z
dc.date.available2015-06-14T13:31:45Z
dc.date.issued2005-10-01
dc.description.abstractThe in vitro activity of tigecycline (former GAR-936), a new semisynthetic tetracycline, was evaluated in comparison with tetracycline and other antimicrobial agents. MATERIAL AND METHODS: A total of 1,326 contemporary clinical isolates collected from the Latin American region were collected in 2000-2002 period and tested with microdilution broth according to the CLSI guidelines. The bacterial pathogens evaluated included Staphylococcus aureus (505), Streptococcus pneumoniae (269), coagulase-negative staphylococci (CoNS; 227), Haemophilus influenzae (129), Enterococcus spp. (80), Moraxella catarrhalis (54), beta-haemolytic streptococci (28), viridans group streptococci (26), and Neisseria meningitidis (8) RESULTS:Tigecycline demonstrated excellent activity against all Gram-positive cocci, with 90% of penicillin-resistant S. pneumoniae strains being inhibited at 0.12 µg/mL, while the same isolates had an MIC90 of > 16 µg/mL for tetracycline. All Enterococcus spp. were inhibited at 0.25 µg/mL of tigecycline. Tigecycline (MIC50, 0.25 µg/mL) was eight-fold more potent than minocycline (MIC50, 2 µg/mL) against oxacillin-resistant S. aureus (ORSA); all ORSA were inhibited at < 2 µg/mL of tigecycline. Tigecycline demonstrated excellent activity (MIC50, 0.5 µg/mL) against CoNS with reduced susceptibility to teicoplanin (MIC, 16 µg/mL). Tigecycline also showed high potency against respiratory pathogens such as M. catarrhalis (MIC50, 0.12 µg/mL) and H. influenzae (MIC50, 0.5 µg/mL). No tigecycline resistant isolates were detected when the proposed susceptible breakpoints (< 4 µg/mL) was applied. CONCLUSIONS: This results indicate that tigecycline has potent in vitro activity against clinically important pathogenic bacteria, including Gram-positive isolates resistant to both tetracycline and minocycline.en
dc.description.affiliationFederal University of São Paulo Division of Infectious Diseases
dc.description.affiliationDepartment of Medicine
dc.description.affiliationThe JMI Laboratories
dc.description.affiliationUnifespUNIFESP, Division of Infectious Diseases
dc.description.sourceSciELO
dc.format.extent348-356
dc.identifierhttp://dx.doi.org/10.1590/S1413-86702005000500001
dc.identifier.citationBrazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 9, n. 5, p. 348-356, 2005.
dc.identifier.doi10.1590/S1413-86702005000500001
dc.identifier.fileS1413-86702005000500001.pdf
dc.identifier.issn1413-8670
dc.identifier.scieloS1413-86702005000500001
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/2706
dc.language.isoeng
dc.publisherBrazilian Society of Infectious Diseases
dc.relation.ispartofBrazilian Journal of Infectious Diseases
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAntimicrobial susceptibilityen
dc.subjecttigecyclineen
dc.subjectLatin America and SENTRYen
dc.titleIn vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin Americaen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
S1413-86702005000500001.pdf
Tamanho:
46.74 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos